PMID- 26313133 OWN - NLM STAT- MEDLINE DCOM- 20160824 LR - 20151107 IS - 1873-3360 (Electronic) IS - 0306-4530 (Linking) VI - 62 DP - 2015 Dec TI - BDNF methylation and depressive disorder in acute coronary syndrome: The K-DEPACS and EsDEPACS studies. PG - 159-65 LID - S0306-4530(15)00886-0 [pii] LID - 10.1016/j.psyneuen.2015.08.013 [doi] AB - OBJECTIVE: Epigenetic regulation investigated by methylation tests has been associated with pathogenesis and treatment response in depressive disorders. However, these hypotheses have rarely been tested in patients with acute coronary syndrome (ACS) vulnerable to depression. This study aimed to investigate whether brain derived neurotrophic factor (BDNF) methylation status is associated with occurrence and treatment response of depressive disorder in ACS. METHODS: Of 969 patients with recently developed ACS were recruited at baseline, 711 were followed 1 year thereafter. Depressive disorder was diagnosed according to DSM-IV criteria, and classified as baseline prevalent, and follow-up incident or persistent depressive disorder according to status at the two examinations. In addition, of 378 baseline participants with depressive disorder, 255 were randomized to a 24-week double blind trial of escitalopram (N=127) or placebo (N=128), while the remaining 123 received conventional medical treatment for ACS. BDNF methylation percentages were estimated using leukocyte DNA, and a range of demographic and clinical characteristics were evaluated as covariates. RESULTS: In logistic regression models, higher BDNF methylation status was independently associated with prevalent depressive disorder at baseline and with its persistence at follow-up. Escitalopram was more effective than placebo for treating depressive disorder in those with a higher methylation, and this effects lead to prevent persistent depressive disorder. CONCLUSIONS: ACS patients with higher BDNF methylation were susceptible to early depressive disorder, and to its persistence one year later. Adequate antidepressants treatment may effective particularly in those with higher BDNF methylation and then can overcome epigenetic vulnerability for depression persistence in ACS patients. ClinicalTrial.gov identifier for the 24 week drug trial, NCT00419471. CI - Copyright (c) 2015 Elsevier Ltd. All rights reserved. FAU - Kim, Jae-Min AU - Kim JM AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: jmkim@chonnam.ac.kr. FAU - Stewart, Robert AU - Stewart R AD - King's College London, Institute of Psychiatry, London, UK. Electronic address: r.stewart@iop.kcl.ac.uk. FAU - Kang, Hee-Ju AU - Kang HJ AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: hjkang82@chonnam.ac.kr. FAU - Bae, Kyung-Yeol AU - Bae KY AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: kybae1@chonnam.ac.kr. FAU - Kim, Sung-Wan AU - Kim SW AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: swkim@chonnam.ac.kr. FAU - Shin, Il-Seon AU - Shin IS AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: isshin@chonnam.ac.kr. FAU - Hong, Young Joon AU - Hong YJ AD - Department of Cardiology, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: hyj200@chonnam.ac.kr. FAU - Ahn, Youngkeun AU - Ahn Y AD - Department of Cardiology, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: cecilyk@chonnam.ac.kr. FAU - Jeong, Myung Ho AU - Jeong MH AD - Department of Cardiology, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: mhjeong@chonnam.ac.kr. FAU - Yoon, Jin-Sang AU - Yoon JS AD - Department of Psychiatry, Chonnam National University Medical School, Gwangju, South Korea. Electronic address: jsyoon@chonnam.ac.kr. LA - eng SI - ClinicalTrials.gov/NCT00419471 PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20150817 PL - England TA - Psychoneuroendocrinology JT - Psychoneuroendocrinology JID - 7612148 RN - 0 (Antidepressive Agents) RN - 0 (Brain-Derived Neurotrophic Factor) RN - 0DHU5B8D6V (Citalopram) SB - IM MH - Acute Coronary Syndrome/complications/*genetics/psychology MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Antidepressive Agents/therapeutic use MH - Brain-Derived Neurotrophic Factor/*genetics MH - Citalopram/therapeutic use MH - *DNA Methylation MH - Depressive Disorder, Major/complications/drug therapy/*genetics/psychology MH - Double-Blind Method MH - Female MH - Humans MH - Male MH - Middle Aged MH - Polymorphism, Genetic MH - Promoter Regions, Genetic MH - Young Adult OTO - NOTNLM OT - Acute coronary syndrome OT - BDNF OT - Depression OT - Epigenetics OT - Methylation EDAT- 2015/08/28 06:00 MHDA- 2016/08/25 06:00 CRDT- 2015/08/28 06:00 PHST- 2015/04/04 00:00 [received] PHST- 2015/07/16 00:00 [revised] PHST- 2015/08/13 00:00 [accepted] PHST- 2015/08/28 06:00 [entrez] PHST- 2015/08/28 06:00 [pubmed] PHST- 2016/08/25 06:00 [medline] AID - S0306-4530(15)00886-0 [pii] AID - 10.1016/j.psyneuen.2015.08.013 [doi] PST - ppublish SO - Psychoneuroendocrinology. 2015 Dec;62:159-65. doi: 10.1016/j.psyneuen.2015.08.013. Epub 2015 Aug 17.